Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Interferon beta-1a in primary progressive MS: an exploratory, randomized, controlled trial.

S M Leary1, D H Miller, V L Stevenson

  • 1NMR Research Unit, Institute of Neurology, University College London, UK.

Neurology
|January 15, 2003
PubMed
Summary

Interferon beta-1a (IFN-β-1a) at 30 mcg was well tolerated in primary progressive multiple sclerosis (PPMS) patients but did not improve disability progression. The 60 mcg dose showed adverse effects.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Anti-HBs Immune Complex Levels: A Novel Marker of Hepatitis Flare Following Nucleos(t)ide Analog Withdrawal in HBeAg-negative Chronic Hepatitis B.

The Journal of infectious diseases·2025
Same author

Balancing Efficiency and Accuracy in Hepatitis C Rapid Antibody Testing: Insights From a Cluster Randomised Crossover Trial.

Journal of viral hepatitis·2025
Same author

Editorial: Ultralow HBsAg Levels and the Prediction of Cure in Chronic Hepatitis B.

Alimentary pharmacology & therapeutics·2025
Same author

New insights into the effects of ethylene on ABA catabolism, sweetening and dormancy in stored potato tubers.

Postharvest biology and technology·2021
Same author

Direct Measurement of Single-Molecule Ligand-Receptor Interactions.

The journal of physical chemistry. B·2020
Same author

Prevalence of baseline HCV NS5A resistance associated substitutions in genotype 1a, 1b and 3 infection in Australia.

Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology·2019

Area of Science:

  • Neurology
  • Immunology
  • Clinical Trials

Background:

  • Primary progressive multiple sclerosis (PPMS) presents unique challenges.
  • PPMS patients have historically been excluded from therapeutic trials.
  • This study focuses on a randomized controlled trial specifically for PPMS.

Purpose of the Study:

  • To evaluate the efficacy and safety of interferon beta-1a (IFN-β-1a) in patients with PPMS.
  • To assess the impact of different doses of IFN-β-1a on disability progression and MRI outcomes.
  • To identify relevant outcome measures for PPMS clinical trials.

Main Methods:

  • A randomized, controlled trial involving 50 PPMS subjects.
  • Intervention groups received weekly intramuscular IFN-β-1a (30 mcg or 60 mcg) or placebo for 2 years.

Related Experiment Videos

  • Primary endpoint: time to sustained disability progression; secondary endpoints: neurological tests and MRI measures (lesion load, atrophy).

    • Main Results:

    • The 30 mcg dose of IFN-β-1a was well tolerated; the 60 mcg dose led to severe side effects.
    • No significant effect of IFN-β-1a on the primary endpoint of disability progression was observed.
    • A reduced accumulation of T2 lesion load was noted with 30 mcg IFN-β-1a, but increased ventricular enlargement occurred with 60 mcg IFN-β-1a.

    Conclusions:

    • Interferon beta-1a at 30 mcg is safe for PPMS patients but lacks efficacy for the primary outcome.
    • The study identified valuable outcome measures for future PPMS research.
    • Higher doses of IFN-β-1a may have detrimental effects on brain volume in PPMS.